The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats

Mari N. Willeman, Sarah E. Mennenga, Ashley L. Siniard, Jason J. Corneveaux, Matt De Both, Lauren T. Hewitt, Candy W.S. Tsang, Jason Caselli, Brittany Braden, Heather Bimonte-Nelson, Matthew J. Huentelman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Enzastaurin is a Protein Kinase C-β selective inhibitor that was developed to treat cancers. Protein Kinase C-β is an important enzyme for a variety of neuronal functions; in particular, previous rodent studies have reported deficits in spatial and fear-conditioned learning and memory with lower levels of Protein Kinase C-β. Due to Enzastaurin’s mechanism of action, the present study investigated the consequences of Enzastaurin exposure on learning and memory in 12-month-old Fischer-344 male rats. Rats were treated daily with subcutaneous injections of either vehicle or Enzastaurin, and behaviorally tested using the spatial reference memory Morris Water Maze. Rats treated with Enzastaurin exhibited decreased overnight retention and poorer performance on the latter testing day, indicating a mild, but significant, memory impairment. There were no differences during the probe trial indicating that all animals were able to spatially localize the platform to the proper quadrant by the end of testing. RNA isolated from the hippocampus was analyzed using Next Generation Sequencing (Illumina). No statistically significant transcriptional differences were noted. Our findings suggest that acute Enzastaurin treatment can impair hippocampal-based learning and memory performance, with no effects on transcription in the hippocampus. We propose that care should be taken in future clinical trials that utilize Protein Kinase C-ß inhibitors, to monitor for possible cognitive effects, future research should examine if these effects are fully reversible.

Original languageEnglish (US)
Article numbere0198256
JournalPLoS One
Volume13
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

middle-aged adults
protein kinase C
Rats
Data storage equipment
Protein Kinase C
rats
learning
hippocampus
Learning
Hippocampus
subcutaneous injection
fearfulness
Protein C Inhibitor
Testing
Subcutaneous Injections
Transcription
Protein Kinase Inhibitors
clinical trials
mechanism of action
rodents

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Willeman, M. N., Mennenga, S. E., Siniard, A. L., Corneveaux, J. J., De Both, M., Hewitt, L. T., ... Huentelman, M. J. (2018). The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats. PLoS One, 13(6), [e0198256]. https://doi.org/10.1371/journal.pone.0198256

The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats. / Willeman, Mari N.; Mennenga, Sarah E.; Siniard, Ashley L.; Corneveaux, Jason J.; De Both, Matt; Hewitt, Lauren T.; Tsang, Candy W.S.; Caselli, Jason; Braden, Brittany; Bimonte-Nelson, Heather; Huentelman, Matthew J.

In: PLoS One, Vol. 13, No. 6, e0198256, 01.06.2018.

Research output: Contribution to journalArticle

Willeman, MN, Mennenga, SE, Siniard, AL, Corneveaux, JJ, De Both, M, Hewitt, LT, Tsang, CWS, Caselli, J, Braden, B, Bimonte-Nelson, H & Huentelman, MJ 2018, 'The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats', PLoS One, vol. 13, no. 6, e0198256. https://doi.org/10.1371/journal.pone.0198256
Willeman MN, Mennenga SE, Siniard AL, Corneveaux JJ, De Both M, Hewitt LT et al. The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats. PLoS One. 2018 Jun 1;13(6). e0198256. https://doi.org/10.1371/journal.pone.0198256
Willeman, Mari N. ; Mennenga, Sarah E. ; Siniard, Ashley L. ; Corneveaux, Jason J. ; De Both, Matt ; Hewitt, Lauren T. ; Tsang, Candy W.S. ; Caselli, Jason ; Braden, Brittany ; Bimonte-Nelson, Heather ; Huentelman, Matthew J. / The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats. In: PLoS One. 2018 ; Vol. 13, No. 6.
@article{0c2db782fa104d0cb572a939dfc38475,
title = "The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats",
abstract = "Enzastaurin is a Protein Kinase C-β selective inhibitor that was developed to treat cancers. Protein Kinase C-β is an important enzyme for a variety of neuronal functions; in particular, previous rodent studies have reported deficits in spatial and fear-conditioned learning and memory with lower levels of Protein Kinase C-β. Due to Enzastaurin’s mechanism of action, the present study investigated the consequences of Enzastaurin exposure on learning and memory in 12-month-old Fischer-344 male rats. Rats were treated daily with subcutaneous injections of either vehicle or Enzastaurin, and behaviorally tested using the spatial reference memory Morris Water Maze. Rats treated with Enzastaurin exhibited decreased overnight retention and poorer performance on the latter testing day, indicating a mild, but significant, memory impairment. There were no differences during the probe trial indicating that all animals were able to spatially localize the platform to the proper quadrant by the end of testing. RNA isolated from the hippocampus was analyzed using Next Generation Sequencing (Illumina). No statistically significant transcriptional differences were noted. Our findings suggest that acute Enzastaurin treatment can impair hippocampal-based learning and memory performance, with no effects on transcription in the hippocampus. We propose that care should be taken in future clinical trials that utilize Protein Kinase C-{\ss} inhibitors, to monitor for possible cognitive effects, future research should examine if these effects are fully reversible.",
author = "Willeman, {Mari N.} and Mennenga, {Sarah E.} and Siniard, {Ashley L.} and Corneveaux, {Jason J.} and {De Both}, Matt and Hewitt, {Lauren T.} and Tsang, {Candy W.S.} and Jason Caselli and Brittany Braden and Heather Bimonte-Nelson and Huentelman, {Matthew J.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1371/journal.pone.0198256",
language = "English (US)",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats

AU - Willeman, Mari N.

AU - Mennenga, Sarah E.

AU - Siniard, Ashley L.

AU - Corneveaux, Jason J.

AU - De Both, Matt

AU - Hewitt, Lauren T.

AU - Tsang, Candy W.S.

AU - Caselli, Jason

AU - Braden, Brittany

AU - Bimonte-Nelson, Heather

AU - Huentelman, Matthew J.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Enzastaurin is a Protein Kinase C-β selective inhibitor that was developed to treat cancers. Protein Kinase C-β is an important enzyme for a variety of neuronal functions; in particular, previous rodent studies have reported deficits in spatial and fear-conditioned learning and memory with lower levels of Protein Kinase C-β. Due to Enzastaurin’s mechanism of action, the present study investigated the consequences of Enzastaurin exposure on learning and memory in 12-month-old Fischer-344 male rats. Rats were treated daily with subcutaneous injections of either vehicle or Enzastaurin, and behaviorally tested using the spatial reference memory Morris Water Maze. Rats treated with Enzastaurin exhibited decreased overnight retention and poorer performance on the latter testing day, indicating a mild, but significant, memory impairment. There were no differences during the probe trial indicating that all animals were able to spatially localize the platform to the proper quadrant by the end of testing. RNA isolated from the hippocampus was analyzed using Next Generation Sequencing (Illumina). No statistically significant transcriptional differences were noted. Our findings suggest that acute Enzastaurin treatment can impair hippocampal-based learning and memory performance, with no effects on transcription in the hippocampus. We propose that care should be taken in future clinical trials that utilize Protein Kinase C-ß inhibitors, to monitor for possible cognitive effects, future research should examine if these effects are fully reversible.

AB - Enzastaurin is a Protein Kinase C-β selective inhibitor that was developed to treat cancers. Protein Kinase C-β is an important enzyme for a variety of neuronal functions; in particular, previous rodent studies have reported deficits in spatial and fear-conditioned learning and memory with lower levels of Protein Kinase C-β. Due to Enzastaurin’s mechanism of action, the present study investigated the consequences of Enzastaurin exposure on learning and memory in 12-month-old Fischer-344 male rats. Rats were treated daily with subcutaneous injections of either vehicle or Enzastaurin, and behaviorally tested using the spatial reference memory Morris Water Maze. Rats treated with Enzastaurin exhibited decreased overnight retention and poorer performance on the latter testing day, indicating a mild, but significant, memory impairment. There were no differences during the probe trial indicating that all animals were able to spatially localize the platform to the proper quadrant by the end of testing. RNA isolated from the hippocampus was analyzed using Next Generation Sequencing (Illumina). No statistically significant transcriptional differences were noted. Our findings suggest that acute Enzastaurin treatment can impair hippocampal-based learning and memory performance, with no effects on transcription in the hippocampus. We propose that care should be taken in future clinical trials that utilize Protein Kinase C-ß inhibitors, to monitor for possible cognitive effects, future research should examine if these effects are fully reversible.

UR - http://www.scopus.com/inward/record.url?scp=85048077638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048077638&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0198256

DO - 10.1371/journal.pone.0198256

M3 - Article

C2 - 29870545

AN - SCOPUS:85048077638

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e0198256

ER -